With the introduction of calcimimetics in CKD patients on dialysis, a significant reduction in serum levels of PTH has been observed, and these, in turn, inhibit the mobilization of calcium and phosphate from bone [8]. This evidence concerns the gene PTH and chronic kidney disease.